In:
Current Oncology, MDPI AG, Vol. 26, No. 2 ( 2019-04-01), p. 270-273
Abstract:
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung carcinoma with a poor prognosis and poor response to chemotherapy and radiotherapy. A previous study reported that psc expresses high levels of PD-L1, suggesting the potential efficacy of immune checkpoint inhibitors in these tumours. We report 2 cases of patients with a lung sarcomatoid carcinoma. Both patients initially underwent curative lung resection, but developed early recurrent disease. Because PD-L1 was highly expressed in the tumour cells, we initiated therapy with nivolumab, which showed good efficacy, almost complete radiologic tumour remission, and a remarkable improvement in the condition of those patients. Immune checkpoint inhibitors targeting PD-1 might be a valuable therapy option for PSCS.
Type of Medium:
Online Resource
ISSN:
1718-7729
Language:
English
Publisher:
MDPI AG
Publication Date:
2019
detail.hit.zdb_id:
2270777-3
Bookmarklink
